Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?
Recent News and Pipeline Developments Theriva Biologics (NYSE American: TOVX) has been in the news for its upcoming conference presentations and strong trial data. On October 13, 2025 the company announced that expanded data from the VIRAGE Phase 2b trial (metastatic pancreatic cancer) will be presented at the ESMO 2025 Congress on October 20sec.gov. In VIRAGE, the oncolytic adenovirus VCN-01 is given with gemcitabine/nab‑paclitaxel standard chemotherapy. Interim abstract data (recently filed with the SEC) show that VCN-01 + chemotherapy substantially improved overall survival (OS) and progression-free survival (PFS) versus chemotherapy alonesec.govsec.gov. Patients receiving VCN-01 saw median OS up to ~11–14 months versus